Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .
from Reuters: Health News https://ift.tt/2QAcGNw
No comments:
Post a Comment